HomeAI · summaries
Storia in 4 fonti
Eli Lilly study aims to bolster case for long-term Zepbound benefits
As Medicare's GLP-1 Bridge program gets underway in earnest and questions remain about the long-term use of these drugs, Eli Lilly is offering a new look at how older adults fare on its medication, | As Medicare's GLP-1 Bridge program gets underway in earnest and questions remain about the long-term use of these drugs, Eli Lilly is offering a new look at how older adults fare on its medication, Zepbound.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial
A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a…
- ·
benzinga.com
Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical C
New Eli Lilly study reveals that Zepbound significantly lowers monthly healthcare costs for older adults with overweight or obesity.
